Publicacions

Practice Recommendations for the Management of MASLD in Primary Care: Consensus Results

C. LIONIS, S. PAPADAKIS, M. ANASTASAKI, E. ALIGIZAKIS, F. ANASTASIOU, S. FRANCQUE, I. GERGIANAKI, J. MENDIVE, M. MARKETOU, J. MURIS, S. MANOLAKOPOULOS, G. PAPATHEODORIDIS, D. SAMONAKIS, E. SYMVOULAKIS and I. TSILIGIANNI
Aten Primaria.2022 Aug; 54(9):102437.doi:10.3390/diseases12080180 PMID:39195179

Background: Despite its high prevalence and impact on health, metabolic dysfunction-associated steatotic liver disease (MASLD) is inadequately addressed in European primary care (PC), with a large proportion of cases going undiagnosed or diagnosed too late. A multi-country European research consortium led a project to design and evaluate a patient-centered, integrated model for MASLD screening, diagnosis, and linkage to specialty care for European PC settings. Based on the lessons from this project, the latest research evidence, and existing guidelines for the management of MASLD, we sought to develop a set of practice recommendations for screening, referral, and management of MASLD in PC. Methods: The Rand/UCLA modified Delphi panel method, with two rounds, was used to reach consensus on practice recommendations. The international panel consisted of experts from six countries, representing family medicine, gastroenterology, hepatology, cardiology, and public health. Initially, fifteen statements were drafted based on a synthesis of evidence from the literature and earlier findings from our consortium. Prior to the consensus meeting, the statements were rated by the experts in the first round. Then, in a hybrid meeting, the experts discussed findings from round one, adjusted the statements, and reassessed the updated recommendations in a second round. Results: In round one, there was already a high level of consensus on 10 out of 15 statements. After round 2, there were fourteen statements with a high degree of agreement (>90%). One statement was not endorsed. The approved recommendations addressed the following practice areas: risk screening and diagnosis, management of MASLD-lifestyle interventions, pharmacological treatment of MASLD/MASH, pharmacological treatment for co-morbidity, integrated care, surgical management, and other referrals to specialists. Conclusions: The final set of 14 recommendations focuses on increasing comprehensive care for MASLD in PC. The recommendations provide practical evidence-based guidance tailored to PC practitioners. We expect that these recommendations will contribute to the ongoing discussion on systematic approaches to tackling MASLD and supporting European PC providers by integrating the latest evidence into practice.

Proton Pump Inhibitors: Rational Use and Use-Reduction – The Windsor Workshop

P. KAHRILAS, F. ANASTASIOU, A. BREDENOORD, H. EL SERAG, J. LABENZ, J. MENDIVE, E. SAVARINO, D. SIFRIM, M. UDRESCU, R. YADLAPATI and A. HUNGIN
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1159/000538399 PMID:38513623

Background: Despite deprescribing initiatives to curb overutilization of proton pump inhibitors (PPIs), achieving meaningful reductions in PPI use is proving a challenge. Summary: An international group of primary care doctors and gastroenterologists examined the literature surrounding PPI use and use-reduction to clarify: (i) what constitutes rational PPI prescribing; (ii) when and in whom PPI use-reduction should be attempted; and (iii) what strategies to use when attempting PPI use-reduction. Key Messages: Before starting a PPI for reflux-like symptoms, patients should be educated on potential causes and alternative approaches including dietary and lifestyle modification, weight loss, and relaxation strategies. When commencing a PPI, patients should understand the reason for treatment, planned duration, and review date. PPI use at hospital discharge should not be continued without a recognized indication for long-term treatment. Long-term PPI therapy should be reviewed at least annually. PPI use-reduction should be based on the lack of a rational indication for long-term PPI use, not concern for PPI-associated adverse events. PPI use-reduction strategies involving switching to on-demand PPI or dose tapering, with rescue therapy for rebound symptoms, are more likely to succeed than abrupt cessation.

Clinical nutrition in primary care: ESPEN position paper

Z. KRZNARIC, D. BENDER, M. KOVAC, C. CUERDA, A. GINKEL-RES, M. HIESMAYR, A. MARINHO, J. MENDIVE, I. MONTEIRO, M. PIRLICH, S. MILANOVIC, N. KOZJEK, S. SCHNEIDER, M. CHOURDAKIS and R. BARAZZONI
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1016/j.clnu.2024.02.017 PMID:38471980

Primary care healthcare professionals (PCHPs) are pivotal in managing chronic diseases and present a unique opportunity for nutrition-related disease prevention. However, the active involvement of PCHPs in nutritional care is limited, influenced by factors like insufficient education, lack of resources, and time constraints. In this position paper The European Society for Clinical Nutrition and Metabolism (ESPEN) promotes the active engagement of PCHPs in nutritional care. We emphasize the importance of early detection of malnutrition by screening and diagnosis, particularly in all individuals presenting with risk factors such as older age, chronic disease, post-acute disease conditions and after hospitalization for any cause. ESPEN proposes a strategic roadmap to empower PCHPs in clinical nutrition, focusing on education, tools, and multidisciplinary collaboration. The aim is to integrate nutrition into medical curricula, provide simple screening tools for primary care, and establish referral pathways to address malnutrition systematically. In conclusion, we urge for collaboration with PCHP organizations to raise awareness, enhance nutrition skills, facilitate dietitian accessibility, establish multidisciplinary teams, and promote referral pathways, thereby addressing the underestimated clinical challenge of malnutrition in primary care. (c) 2024 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Assessment and treatment of refluxlike symptoms in the community: a multidisciplinary perspective

P. KAHRILAS, F. ANASTASIOU, K. BARRETT, L. BEH, D. CHINZON, B. DOERFLER, E. LÓPEZ-PINTOR, J. MAIMIN, J. MENDIVE, T. TAFT and A. HUNGIN
Aten Primaria.2022 Aug; 54(9):102437.doi:10.3399/bjgp24X737349 PMID:38664044

Heartburn and regurgitation are extremely common in Western societies, largely driven by obesity, age-related anatomical degradation of anti-reflux mechanisms, dietary, and psychological factors. Widespread diagnosis of gastro-oesophageal reflux disease (GORD) has led to liberal prescribing of proton pump inhibitors (PPIs) to ameliorate these symptoms. This strategy of first-line acid suppression is somewhat unsatisfactory for reflux-like symptoms for several reasons: 1) it equates all symptoms with a ‘disease’, regardless of their frequency, intensity, or potential morbidity; 2) it ignores symptom determinants other than acid reflux; and 3) it needlessly medicalises harmless symptoms compounding patient fear and hypervigilance, often reducing quality of life and driving healthcare utilisation.

COMPARISON BETWEEN 2021 NATIONAL HYPERTENSION GUIDELINES AND 2023 EUROPEAN SOCIETY OF HYPERTENSION GUIDELINES

M. ARTERO, M. SALGUEIRO, J. BORRELL, J. BONET, O. NADAL, M. CAMPS, B. LÓPEZ, M. COSTA, L. VILA, M. PINEDA, N. BACARDIT, C. BLANCO, G. DE TUERO, E. BARGALLO, M. COLL and M. VON WICHMAN
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1097/01.hjh.0001021928.58444.11 PMID:

HYPERTENSION GAMING: A NEW DIVULGATION METHOD FOR GUIDELINES

J. BORRELL, M. CAMPS, O. NADAL, M. SALGUEIRO, M. ARTERO, M. NICOLAU, L. VILA, M. EUSTAQUIO, M. TODÓ, M. COSTA, J. UGENA, G. DE TUERO, M. COLL, J. VILAUBI and E. BARGALLÓ
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1097/01.hjh.0001021920.91520.dc PMID:

Impact of a pharmaceutical algorithm on patients with upper-gastrointestinal symptoms: A pre-post intervention study

M. PUIG-MOLTO, B. LUMBRERAS, J. MENDIVE and E. LOPEZ-PINTOR
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1016/j.ypmed.2024.107885 PMID:38316273

Objective: To evaluate the algorithm impact on the upper gastrointestinal patients’ symptoms (PROMs) and satisfaction with pharmaceutical care received (PREMs). Methods: The algorithm was previously developed by clinicians and pharmacists, through a pre-post intervention study in Spain (June-October 2022). We included 1221 patients who were seeking advice and/or medication for symptoms at 134 community pharmacies. Patients’ sociodemographic and clinical variables were assessed at baseline and were classified in accordance with the Gastroesophageal Reflux Disease Impact Scale (GIS) into patients with either epigastric, retrosternal or overlapping symptoms. Interventions included medical referral; education on healthy habits; prescription of an OTC treatment or a non-pharmacologic prescription. Fourteen days later, patients were assessed through: a) the change on the GIS score, and b) patients’ satisfaction with pharmaceutical care received. Results: Most patients reported overlapping symptoms (660, 54.0%), 171 (14.0%) reported epigastric symptoms and 390 (32.0%) retrosternal symptoms. Patients with epigastric symptoms did not show a difference in the GIS score after the intervention while those with retrosternal symptoms and those with overlapping symptoms did (mean 1.09 (4.28 SD), p < 0.001 and mean 3.18 (6.01 SD), p < 0.001, respectively). Patients who received education on healthy habits and those with a prescription of a pharmacological treatment (antiacids in monotherapy and alginates-antiacids) showed an increase in the GIS score. Patients' satisfaction with pharmaceutical care received was over 99.2% of sample. Conclusion: Implementation of the upper-gastrointestinal symptoms algorithm in Community pharmacies had a positive impact on patients' symptoms, quality of life, and satisfaction with pharmaceutical care received.

Management advice for patients with reflux-like symptoms: an evidence-based consensus

A. HUNGIN, R. YADLAPATI, F. ANASTASIOU, A. BREDENOORD, H. EL SERAG, P. FRACASSO, J. MENDIVE, E. SAVARINO, D. SIFRIM, M. UDRESCU and P. KAHRILAS
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1097/MEG.0000000000002682 PMID:38006602

Patients with reflux-like symptoms (heartburn and regurgitation) are often not well advised on implementing individualised strategies to help control their symptoms using dietary changes, lifestyle modifications, behavioural changes or fast-acting rescue therapies. One reason for this may be the lack of emphasis in management guidelines owing to ‘low-quality’ evidence and a paucity of interventional studies. Thus, a panel of 11 gastroenterologists and primary care doctors used the Delphi method to develop consolidated advice for patients based on expert consensus. A steering committee selected topics for literature searches using the PubMed database, and a modified Delphi process including two online meetings and two rounds of voting was conducted to generate consensus statements based on prespecified criteria (67% voting ‘strongly agree’ or ‘agree with minor reservation’). After expert discussion and two rounds of voting, 21 consensus statements were generated, and assigned strength of evidence and Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) rating. Eleven statements achieved the strongest (100%) agreement: five are related to diet and include identification and avoidance of dietary triggers, limiting alcohol, coffee and carbonated beverages, and advising patients troubled by postprandial symptoms not to overeat; the remaining six statements concern advice around smoking cessation, weight loss, raising the head-of-the-bed, avoiding recumbency after meals, stress reduction and alginate use. The aim of developing the consensus statements is that they may serve as a foundation for tools and advice that can routinely help patients with reflux-like symptoms better understand the causes of their symptoms and manage their individual risk factors and triggers.

CHRONIFICATION IN THE USE OF BENZODIACEPINES: INCIDENCE STRATIFIED BY SEX AND AGE GROUPS

I. AZNAR-LOU, M. PEÑARRUBIA-MARIA and L. PARKER
Aten Primaria.2022 Aug; 54(9):102437.doi: PMID:

INDEPENDENT ONLINE MEDICAL EDUCATION SIGNIFICANTLY IMPROVES PHYSICIAN KNOWLEDGE REGARDING THE BURDEN OF HEPATITIS DELTA VIRUS INFECTION AND BEST PRACTICE IN SCREENING AND DIAGNOSIS

J. DUFFEY, G. GRIFFITHS, T. KUSHNER, J. MENDIVE, F. ZOULIM and M. BUTI
Aten Primaria.2022 Aug; 54(9):102437.doi: PMID:

Patronat

Col·laboradors

Acreditacions